Fabtech Technologies Limited delivered robust financial performance in FY26, achieving total income growth of 28.4% year-on-year to ₹431.33 crore despite challenging global macroeconomic conditions. The company's EBITDA increased by 18.29% to ₹55.56 crore, demonstrating resilience in execution capabilities across its international operations spanning over 60 major geographies.

Strong Financial Performance and Balance Sheet Transformation

The company's financial metrics showed substantial improvement across key parameters during FY26:

A strategic equity infusion of approximately ₹230 crore fundamentally strengthened the company's balance sheet, positioning it for future expansion. The company achieved cash flow positive status, turning from negative ₹36 crore to positive ₹50 lakh, while reducing current borrowings from ₹54 crore to ₹42 crore.

Geographic Revenue Distribution and Market Expansion

The company's global business operations showed strong performance across key markets, with UAE emerging as the largest contributor:

The company's expansion strategy focuses on GCC localization through subsidiaries and joint ventures, including 100% subsidiaries in UAE and Saudi Arabia, 33.33% stake in Mark Maker for process equipment, and strategic partnerships across pharmaceutical emerging markets.

Q4 FY26 Performance Highlights

The fourth quarter demonstrated particularly strong execution with total income reaching ₹168.24 crore, representing 22% year-on-year growth. Quarterly net profit rebounded to ₹22.06 crore, reflecting improved operational strength and providing momentum entering the new fiscal year.

Order Book and Project Pipeline

Fabtech Technologies maintains a robust order book exceeding ₹900 crore, providing revenue visibility for 18-24 months. The company has successfully increased project ticket sizes from earlier $30-40 million to current orders worth $70 million, focusing on end-to-end turnkey solutions.

Recent project wins include:

Strategic Outlook and Growth Projections

Management projects approximately 25% growth for the upcoming period, alongside PAT margin improvement towards 9.9% to 10.5% range. The company's hot lead pipeline includes close to $200 million in active proposals across pharmaceutical, healthcare, and biotech sectors.

The expansion into animal health segments, medical devices, and veterinary vaccines has opened new revenue streams, while the company's integrated design-build model continues to provide competitive advantages in regulatory compliance across WHO, EU-GMP, USFDA, and UKMHRA guidelines.

Operational Challenges and Mitigation

Despite strong revenue growth, the company faced margin pressures due to global supply chain disruptions, with raw material costs increasing by approximately 33% and execution costs rising by 43% due to remobilization requirements amid geopolitical tensions. However, the company's localized presence and variation clauses in contracts helped mitigate these impacts while maintaining client commitments.

Fabtech Technologies Limited has officially announced its audited standalone and consolidated financial results for Q4 and FY26, demonstrating resilient performance amid strategic positioning as a global life science infrastructure platform. The company reported consolidated total income of ₹431.33 crore with a profit after tax of ₹38.36 crore for FY26.

Financial Performance Highlights

The company delivered strong operational performance across key financial metrics for FY26:

The financial results have been adjusted for exceptional items (TSA) of ₹1.77 crore in FY26 and ₹17.85 crore in FY25, highlighting consistent operational strength.

Q4FY26 Performance and Strategic Focus

For Q4FY26, the company reported income growth of 22.00% to ₹168.24 crore with net profit of ₹22.06 crore, marking a solid quarterly turnaround. The performance reflects the company's conscious strategic shift towards building long-term infrastructure capabilities rather than focusing solely on near-term revenue acceleration.

Management Guidance and Future Outlook

During the earnings conference call, management provided comprehensive guidance for upcoming financial years:

Management outlined internal operational targets including a contribution margin of around 45.00%, EBITDA between 13.00% and 14.00%, and PAT between 9.00% and 11.00%. The consolidated revenue targets for FY27, previously stated as ₹530 crores to ₹600 crores, remain consistent with earlier projections.

Regulatory Compliance and Newspaper Publication

Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Fabtech Technologies has published information about its audited standalone and consolidated financial results in newspapers on April 29, 2026. The company informed both NSE and BSE about the newspaper publication compliance.

The newspaper publications are also available on the company's website at fabtechnologies.com, along with the financial results filed with stock exchanges.

Earnings Conference Call Recording Available

Following the announcement of Q4FY26 results, Fabtech Technologies has made available the recording of its earnings conference call held on April 28, 2026. The conference call was conducted to discuss the company's audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.

The recording provides detailed insights into the company's financial performance and management commentary on strategic initiatives.

Strategic Outlook and Growth Initiatives

Management expects gradual margin expansion trajectory to approximately 9.90%-10.50%, supported by operating leverage and scale benefits over FY27. The company is actively evaluating multiple strategic acquisition opportunities to strengthen capabilities and expand global footprint within the life science infrastructure ecosystem. With front-loaded infrastructure investments, Fabtech is positioned to efficiently capitalize on large-scale project opportunities as demand accelerates.

Balance Sheet Strengthening

The company strengthened its foundation through a strategic equity infusion of approximately ₹230 crore, entering FY27 with its strongest balance sheet to date. Management remains focused on cash and collections, prioritizing receivables management to support sustainable growth while maintaining strong liquidity position.